<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551989</url>
  </required_header>
  <id_info>
    <org_study_id>213684</org_study_id>
    <nct_id>NCT04551989</nct_id>
  </id_info>
  <brief_title>Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan</brief_title>
  <acronym>MARS</acronym>
  <official_title>A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as the Churg-Strauss&#xD;
      syndrome, is a systemic necrotizing vasculitis that affects small and medium sized blood&#xD;
      vessels. NUCALA® (mepolizumab 300 milligrams [mg], subcutaneous administration) was approved&#xD;
      in Japan in 2018 for the treatment of EGPA in adult participants. This is a single-arm,&#xD;
      multi-center, prospective, non-interventional study that aims to assess long-term (2 to 4&#xD;
      years) real-world safety and effectiveness of NUCALA. Approximately 120 participants who&#xD;
      completed the NUCALA Post Marketing Surveillance (PMS) study (National Clinical Trial&#xD;
      [NCT]03557060) will be enrolled in the study.&#xD;
&#xD;
      NUCALA is a registered trademark of GlaxoSmithKline (GSK) group of companies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">April 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse events (AEs), Serious adverse events (SAEs) and Adverse events of special interest (AESI)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>AEs, SAEs, and AESIs will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse drug reactions (ADRs)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>ADRs related to NUCALA will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical symptoms</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Clinical symptoms relevant to EGPA in systemic vasculitis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with EGPA relapse</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>EGPA relapse is defined as any of the following with worsening EGPA: increased dose of oral corticosteroids (OCS), initiation/increased dose of immuno-suppressive agents or EGPA treatment with hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hospitalization for EGPA-related events</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Participants with hospitalization for EGPA-related events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with emergency room/unscheduled visits for EGPA-related events</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Participants with emergency room/unscheduled visits for EGPA-related events will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants receiving prednisolone-equivalent of OCS over 96 weeks</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Number of participants receiving prednisolone-equivalent of OCS over 96 weeks will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants in each category of average daily prednisolone-equivalent of OCS over 96 weeks</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Percentage of participants in each category of average daily prednisolone-equivalent of OCS over 96 weeks will be assessed. The dosing categories will include: zero, greater than (&gt;)0 to less than or equal to (&lt;=)4.0 mg/day, &gt;4.0 to &lt;=7.5 mg/day, &gt;7.5 mg/day.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Churg-Strauss Syndrome</condition>
  <arm_group>
    <arm_group_label>Participants with EGPA who have received NUCALA treatment</arm_group_label>
    <description>Data will be collected of participants who have already received NUCALA for 96 weeks in routine clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with EGPA who have already received NUCALA treatment for 96 weeks after&#xD;
        its market launch in Japan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants with EGPA of &gt;=20 years of age inclusive, at the time of signing&#xD;
             the informed consent.&#xD;
&#xD;
          -  Participants must have a current clinical diagnosis of EGPA by physician.&#xD;
&#xD;
          -  Participants have continuously used NUCALA for at least 96 weeks for the treatment of&#xD;
             EGPA as mentioned in the current label in Japan.&#xD;
&#xD;
             • Participants thus were registered and completed the NUCALA PMS study (special drug&#xD;
             use investigation; Protocol Number 208505, NCT03557060) prior to be enrolled in this&#xD;
             study.&#xD;
&#xD;
          -  Physician's decision to continue treatment with NUCALA for the treatment of EGPA as&#xD;
             mentioned in the current label in Japan.&#xD;
&#xD;
          -  Prior to commencing any study related activities, participants must be able and&#xD;
             willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have previously discontinued NUCALA treatment for EGPA for more than&#xD;
             12 weeks.&#xD;
&#xD;
          -  Participating in another clinical trial within the past 12 months, in which the&#xD;
             participant has been exposed to an investigational or non-investigational&#xD;
             pharmaceutical product.&#xD;
&#xD;
          -  Participants with any reasons that in physician's opinion would place the participants&#xD;
             at risk.&#xD;
&#xD;
          -  Participants who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>653-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>670-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>674-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>675-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>241-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kochi</city>
        <zip>780-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>510-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>511-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>533-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>350-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shiga</city>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>430-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>436-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>183-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>190-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>194-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tottori</city>
        <zip>680-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wakayama</city>
        <zip>640-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yamaguchi</city>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NUCALA</keyword>
  <keyword>Eosinophilic granulomatosis with polyangiitis</keyword>
  <keyword>Real world setting</keyword>
  <keyword>Long term safety and efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

